Merck & Co., Inc. (MRK)
After hours:
| Previous Close | 104.10 |
| Open | 104.82 |
| Bid | 105.39 x 2200 |
| Ask | 106.18 x 800 |
| Day's Range | 104.82 - 106.91 |
| 52 Week Range | 78.77 - 115.49 |
| Volume | |
| Avg. Volume | 8,751,701 |
| Market Cap | 268.372B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 38.23 |
| EPS (TTM) | 2.77 |
| Earnings Date | Apr 27, 2023 |
| Forward Dividend & Yield | 2.92 (2.76%) |
| Ex-Dividend Date | Mar 14, 2023 |
| 1y Target Est | 118.04 |
- Zacks
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
- Zacks
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
- Reuters
UPDATE 1-Two new vaccines against bird flu effective in Dutch lab -govt
Two vaccines tested by a Dutch veterinary research centre have proved effective against highly infectious bird flu in a first experiment conducted under a controlled environment, the Dutch government said on Friday. "Not only did the vaccines give poultry used in the lab protection against disease symptoms but they also countered the spreading of the bird flu," the government said in a statement. One vaccine was produced by France's Ceva Animal Health and the other by Germany's Boehringer Ingelheim, an official document on the Dutch government website showed.
